ADB-HEXINACA is classified as a synthetic cannabinoid. Synthetic cannabinoids have been reported to cause psychoactive effects similar to delta-9-tetrahydrocannabinol (THC).
Synthetic cannabinoids have caused adverse events, including deaths. ADB-PINACA and ADB-BINACA (ADB-BUTINACA) are structurally similar synthetic cannabinoids.
ADB-PINACA is a Schedule I substance in the United States; ADB-HEXINACA is not explicitly federally scheduled, although this drug may be controlled under individual state regulations.
ADB-HEXINACA has been identified in 2021 at the Pinellas County Forensic Lab in Florida.